Is Apellis Pharmaceuticals Stock a Good Investment?
Apellis Pharmaceuticals Investment Advice | APLS |
- Examine Apellis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Apellis Pharmaceuticals' leadership team and their track record. Good management can help Apellis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Apellis Pharmaceuticals' business and its evolving consumer preferences.
- Compare Apellis Pharmaceuticals' performance and market position to its competitors. Analyze how Apellis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Apellis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Apellis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Apellis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Apellis Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Apellis Pharmaceuticals Stock
Researching Apellis Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.6. Apellis Pharmaceuticals had not issued any dividends in recent years.
To determine if Apellis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Apellis Pharmaceuticals' research are outlined below:
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| Apellis Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 709.95 M. Net Loss for the year was (197.88 M) with profit before overhead, payroll, taxes, and interest of 336.07 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (87.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Apellis Pharmaceuticals Gets a Hold from Scotiabank - The Globe and Mail |
Apellis Pharmaceuticals Quarterly Accounts Payable |
|
Apellis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Apellis Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Apellis Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2025-02-25 | 2024-12-31 | -0.4019 | -0.29 | 0.1119 | 27 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 | ||
2024-11-05 | 2024-09-30 | -0.3 | -0.4624 | -0.1624 | 54 | ||
2019-05-07 | 2019-03-31 | -0.67 | -0.87 | -0.2 | 29 |
Apellis Pharmaceuticals Target Price Consensus
Apellis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Apellis Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Strong Buy |
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationApellis Pharmaceuticals Target Price Projection
Apellis Pharmaceuticals' current and average target prices are 23.38 and 45.85, respectively. The current price of Apellis Pharmaceuticals is the price at which Apellis Pharmaceuticals is currently trading. On the other hand, Apellis Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Apellis Pharmaceuticals Market Quote on 26th of March 2025
Target Price
Analyst Consensus On Apellis Pharmaceuticals Target Price
Apellis Pharmaceuticals Analyst Ratings
Apellis Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Apellis Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Apellis Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Apellis Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Apellis Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 2.6 M | Fmr Inc | 2024-12-31 | 2.1 M | Braidwell Lp | 2024-12-31 | 2.1 M | Aqr Capital Management Llc | 2024-12-31 | 1.9 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Deutsche Bank Ag | 2024-12-31 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Bank Of America Corp | 2024-12-31 | 1.7 M | Polar Capital Holdings Plc | 2024-12-31 | 1.6 M | Venbio Select Advisor Llc | 2024-12-31 | 12.2 M | Ecor1 Capital, Llc | 2024-12-31 | 11.9 M |
Apellis Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.98 B.Market Cap |
|
Apellis Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.87) | (0.91) |
Determining Apellis Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Apellis Pharmaceuticals is a good buy. For example, gross profit margin measures Apellis Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Apellis Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Check Apellis Pharmaceuticals' Beneish M Score to see the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.
Evaluate Apellis Pharmaceuticals' management efficiency
Apellis Pharmaceuticals has return on total asset (ROA) of (0.1232) % which means that it has lost $0.1232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9355) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2025. Return On Capital Employed is likely to drop to -0.35 in 2025. At this time, Apellis Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2025, whereas Other Current Assets are likely to drop slightly above 26.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.84 | 1.91 | |
| Tangible Book Value Per Share | 1.84 | 1.91 | |
| Enterprise Value Over EBITDA | (16.97) | (16.12) | |
| Price Book Value Ratio | 17.30 | 18.84 | |
| Enterprise Value Multiple | (16.97) | (16.12) | |
| Price Fair Value | 17.30 | 18.84 | |
| Enterprise Value | 1.5 B | 1.6 B |
The decision-making processes within Apellis Pharmaceuticals are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.92 |
Basic technical analysis of Apellis Stock
As of the 26th of March, Apellis Pharmaceuticals shows the mean deviation of 2.11, and Risk Adjusted Performance of (0.13). Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apellis Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 23.38 per share. Given that Apellis Pharmaceuticals has information ratio of (0.17), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Apellis Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Apellis Pharmaceuticals' Outstanding Corporate Bonds
Apellis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Apellis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Apellis bonds can be classified according to their maturity, which is the date when Apellis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Apellis Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Apellis Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | (604.27) | |||
| Standard Deviation | 3.11 | |||
| Variance | 9.67 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 20.77 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 4.11 | |||
| Skewness | (2.00) | |||
| Kurtosis | 10.72 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | (604.27) | |||
| Standard Deviation | 3.11 | |||
| Variance | 9.67 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 20.77 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 4.11 | |||
| Skewness | (2.00) | |||
| Kurtosis | 10.72 |
Consider Apellis Pharmaceuticals' intraday indicators
Apellis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apellis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 23.38 | |||
| Day Typical Price | 23.38 | |||
| Price Action Indicator | (0.19) | |||
| Period Momentum Indicator | (0.38) | |||
| Relative Strength Index | 37.01 |
Apellis Pharmaceuticals Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
| 3rd of February 2025 Other Reports | ViewVerify |
Apellis Stock media impact
Far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. That information is available publicly through Apellis media outlets and privately through word of mouth or via Apellis internal channels. However, regardless of the origin, that massive amount of Apellis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Apellis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Apellis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Apellis Pharmaceuticals.
Apellis Pharmaceuticals Corporate Management
| James CPA | Corporate VP | Profile | |
| Cedric MD | President, CoFounder | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Karen Lewis | Chief Officer | Profile | |
| Nur Nicholson | Chief Officer | Profile |
Already Invested in Apellis Pharmaceuticals?
The danger of trading Apellis Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apellis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apellis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apellis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.